My Stocks Explore Events Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Live today
{{event.ticker}} @{{event.event_utc_datetime | date:'h:mm a'}}
{{market.market_short_name}} {{market.last_price | number : 2}}
AlphaStreet

Want to join the conversation?


$ROST {{ '2016-08-18T21:01:23+0000' | timeago}} • Webcast

David Mann of Johnson Rice & Co. asks about the packaway expense differential impacting 3Q16 versus 4Q16. $ROST said the difference between 3Q16 and 4Q16 is mainly due to the timing of packaway-related costs. 3Q16 and 4Q16 taken together implies a 5-10% EPS growth on a 1-2% comp vs. a 9% increase in 1H16 at the 3% comp.

User Frankie Joe {{ '2017-02-28T13:37:27+0000' | timeago}}

Samsung's not looking good! South Korea will indict their top boss-to-be Lee Jae-yong for corruption.

User Ashton Alloway {{ '2017-02-28T12:20:18+0000' | timeago}}

$TWTR mentions Snap as one of its fiercest rivals in its 10K filing. Great head start for Snap ahead of IPO!

User Johney Kingston {{ '2017-02-27T20:48:18+0000' | timeago}}

$WMT has indeed intensified the grocery price competition..Watch out $KR and Aldi.

User Felix Nilsson {{ '2017-02-27T20:41:52+0000' | timeago}}

The increasing US oil output seems to offset the bets raised by investors a week ago on increasing Brent crude oil prices.

User Nick Velez {{ '2017-02-27T20:22:11+0000' | timeago}}

Treasury yields moved higher on Monday as investors were cautious to make big government bonds investments ahead of President Donald Trump's first congressional address.

$PRGO {{ '2017-02-28T14:30:10+0000' | timeago}} • Announcement

$PRGO agreed to divest Tysabri royalty stream. Royalty Pharma will buy all of $PRGO's rights to receive Tysabri royalty payments from and after Jan. 1, 2017, which $PRGO has under agreement with $BIIB. Tysabri is FDA approved treatment for multiple sclerosis. $PRGO acquired Tysabri royalty stream rights through 2013 acquisition of Elan Corp. plc.

$PRGO {{ '2017-02-28T14:25:16+0000' | timeago}} • Announcement

$PRGO agreed to divest Tysabri royalty stream for up to $2.85Bil. The consideration composed of $2.2Bil in cash at closing and up to $650MM in potential milestone payments based upon future global net sales of Tysabri in 2018 and 2020.

$ESV {{ '2017-02-28T14:24:36+0000' | timeago}} • Announcement

During 4Q16, $ESV's Floater revenues declined 38% YoY to $303MM,due to fewer rig operating days. Jackup revenues fell 39% to $187MM, mainly due to fewer rig operating days.

$ESV {{ '2017-02-28T14:20:31+0000' | timeago}} • Announcement

Offshore drilling company $ESV reported 4Q16 net income of $39MM, or $0.13 per share, compared to net loss of $2.47Bil, or $10.64 per share during 4Q15. Revenues declined 39% YoY to $505MM, mainly due to decline in reported utilization to 51%.

$PRGO {{ '2017-02-28T14:18:53+0000' | timeago}} • Announcement

$PRGO agreed to divest its rights to the royalty stream from the global net sales of the multiple sclerosis drug Tysabri (natalizumab) to RPI Finance Trust, an affiliate of Royalty Pharma. This transaction is valued at a total consideration of up to $2.85Bil. This transaction is expected to close within 30 business days.